Dare Bioscience, Inc.DAREEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on women’s health solutions. It develops innovative therapies for gynecological conditions, reproductive health, and sexual wellness, targeting unmet medical needs primarily in the U.S. market, with plans to expand to other global developed markets.
Revenue
$41.7K
Gross Profit
N/A
Operating Profit
$-4.7M
Net Profit
$-4.7M
Gross Margin
N/A
Operating Margin
-11228.7%
Net Margin
-11279.4%
YoY Growth
-95.8%
EPS
$-0.55
Dare Bioscience, Inc. Q3 FY2024 Financial Summary
Dare Bioscience, Inc. reported revenue of $41.7K (down 95.8% YoY) for Q3 FY2024, with a net profit of $-4.7M (up 43.3% YoY) (-11279.4% margin).
Key Financial Metrics
| Total Revenue | $41.7K |
|---|---|
| Net Profit | $-4.7M |
| Gross Margin | N/A |
| Operating Margin | -11228.7% |
| Report Period | Q3 FY2024 |
Dare Bioscience, Inc. Quarterly Revenue & Net Profit History
Dare Bioscience, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2025 | $25.4K | +173.3% | $-4.4M | -17219.1% |
| Q3 FY2024 | $41.7K | -95.8% | $-4.7M | -11279.4% |
| Q2 FY2024 | $22.4K | — | $12.9M | 57539.2% |
| Q1 FY2024 | $9.3K | — | $-6.8M | -72622.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | |
|---|---|---|---|---|
| Revenue | $9302 | $22438 | $41691 | $25427 |
| YoY Growth | N/A | N/A | -95.8% | 173.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | |
|---|---|---|---|---|
| Assets | $13.0M | $23.6M | $18.1M | $18.6M |
| Liabilities | $24.0M | $20.9M | $19.5M | $28.2M |
| Equity | $-11.0M | $2.7M | $-1.5M | $-9.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | |
|---|---|---|---|---|
| Operating CF | $-6.8M | $12.9M | $-5.9M | $-5.5M |